Dr. Zandberg on Durvalumab Trial in Head and Neck Cancer

Dan Zandberg, MD
Published: Friday, Sep 22, 2017



Dan Zandberg, MD, assistant professor, medicine, University of Maryland School of Medicine, discusses the HAWK trial of durvalumab (Imfinzi) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Overall response rate in this phase II trial was 16% with durable responses. Median overall survival was 7 months and a 1-year survival rate of 33%.

Additionally, patients who were HPV positive had a response rate higher than those who were HPV negative.
 
SELECTED
LANGUAGE


Dan Zandberg, MD, assistant professor, medicine, University of Maryland School of Medicine, discusses the HAWK trial of durvalumab (Imfinzi) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Overall response rate in this phase II trial was 16% with durable responses. Median overall survival was 7 months and a 1-year survival rate of 33%.

Additionally, patients who were HPV positive had a response rate higher than those who were HPV negative.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Publication Bottom Border
Border Publication
x